Subscribe
Healthcare

Trump administration fast-tracks ibogaine research for PTSD

By Gabrielle M. Etzel
Published
Add Washington Examiner on Google

The Trump administration announced on Thursday a multi-department investment in fast-tracking research for the psychotropic drug ibogaine to treat post-traumatic stress disorder and other serious mental illnesses.

Health and Human Services Secretary Robert F. Kennedy Jr. announced a more than $25 million investment from his department, along with the Department of Veterans Affairs, to speed up research on ibogaine as a possible treatment for PTSD, addiction, and other mental health disorders.

Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.

Tag:

Department of Health and Human Services Department of Veterans Affairs Doug Collins Drugs Healthcare Mental Health PTSD Robert F. Kennedy Jr. Veterans